Potassium Correction for RAAS Optimization in Chronic Kidney Disease

Summary

The goal of this placebo-controlled, double-blinded cross-over trial is to test whether patiromer, compared with placebo, better enables up-titration of RAAS-blocker treatment in patients with chronic kidney disease stage 3b/4.

The main questions it aims to answer are:

* Does patiromer allow uptitration of irbesartan, resulting in a significant reduction in albuminuria and blood pressure?
* Does patiromer allow uptitration of irbesartan, resulting in a significant reduction in blood pressure?

The trial contains the following interventions:

* Participants will be switched from their ACEi/ARB to a standardised dose of irbesartan (150 mg/d).
* During two 12-week study periods, participants will receive either patiromer 8.4 g/d or placebo. The order of study periods is randomized.
* At the start of each study period irbesartan will be up-titrated to 300 mg/d.
* After 1 and 6 weeks, at both periods, plasma potassium will be measured and the irbesartan dose will be reduced to 150 mg/d in case plasma potassium exceeds 5.0 mmol/L.
* At 12 weeks from the start of the study period, the endpoints will be assessed.
* Between the two study periods, there is a 6-week washout. Irbesartan dose during the wash-out period will be 150mg/d. After washout, participants will switch from the patiromer arm to the placebo arm or vice versa.

Conditions

• Chronic Kidney Diseases
• Hyperkalemia
• Hypertension

Interventions

DRUG

Patiromer 8400 MG [Veltassa]

Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.

DRUG

Placebo

Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.

Sponsors & Collaborators

• Amsterdam University Medical Center

  collaborator OTHER

• Frisius Medisch Centrum

  collaborator OTHER

• Isala

  collaborator OTHER

• Vifor Pharma, Inc.

  collaborator INDUSTRY

• Dutch Kidney Foundation

  collaborator OTHER

• Health Holland

  collaborator OTHER

• University Medical Center Groningen

  lead OTHER

Principal Investigators

• Liffert Vogt, prof. dr. · Amsterdam University Medical Centre

• Aaltje Adema, dr. · Frisius Medisch Centrum

• Femke Waanders, dr. · Isala Zwolle

• Martin de Borst, prof. dr. · University Medical Center Groningen

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-04-01

Primary Completion

2026-12-31

Completion

2027-12-31

Countries

• Netherlands

Study Locations